# ECHELON-1 (NCT01712490)

> A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

No report yet. It can be ordered.

- Drugs tested: brentuximab vedotin
- Indication: previously untreated advanced-stage classical Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01712490
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: Hodgkin Lymphoma
- Interventions: brentuximab vedotin; doxorubicin; bleomycin; vinblastine; dacarbazine
- Enrollment: 1334
- Primary outcome: Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)

## Indexed commentary on ECHELON-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 86
- Podcasts: 35
- YouTube: 29
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=echelon-1-nct01712490

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01712490", "email": "<work email>"}; the inbox owner confirms by the emailed link.